2024-05-03 14:37:00 ET
Summary
- Zoetis is a leader in animal health, focusing on R&D to develop innovative medicines and technologies for pets and livestock.
- Concerns have arisen about the safety of their drugs, but Zoetis appears confident and reported impressive revenue growth.
- The stock experienced volatility but has since recovered, and the long-term outlook for Zoetis remains positive.
- Zoetis' Librela and Solensia franchise has the potential to be a major growth driver, reaching over $1 billion in annual sales.
Investment Thesis
Animal health leader Zoetis ( ZTS ) boasts a strong market position and emphasizes R&D to deliver innovative medicines, vaccines, and technologies for pets and livestock. Recent examples include Librela and Solensia, showcasing their commitment to improving pet lives....
Read the full article on Seeking Alpha
For further details see:
Zoetis: Long-Term Buy Despite Safety Concerns